Literature DB >> 17562708

Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.

Diane P Hanger1, Helen L Byers, Selina Wray, Kit-Yi Leung, Malcolm J Saxton, Anjan Seereeram, C Hugh Reynolds, Malcolm A Ward, Brian H Anderton.   

Abstract

Tau in Alzheimer disease brain is highly phosphorylated and aggregated into paired helical filaments comprising characteristic neurofibrillary tangles. Here we have analyzed insoluble Tau (PHF-tau) extracted from Alzheimer brain by mass spectrometry and identified 11 novel phosphorylation sites, 10 of which were assigned unambiguously to specific amino acid residues. This brings the number of directly identified sites in PHF-tau to 39, with an additional six sites indicated by reactivity with phosphospecific antibodies to Tau. We also identified five new phosphorylation sites in soluble Tau from control adult human brain, bringing the total number of reported sites to nine. To assess which kinases might be responsible for Tau phosphorylation, we used mass spectrometry to determine which sites were phosphorylated in vitro by several kinases. Casein kinase 1delta and glycogen synthase kinase-3beta were each found to phosphorylate numerous sites, and each kinase phosphorylated at least 15 sites that are also phosphorylated in PHF-tau from Alzheimer brain. A combination of casein kinase 1delta and glycogen synthase kinase-3beta activities could account for over three-quarters of the serine/threonine phosphorylation sites identified in PHF-tau, indicating that casein kinase 1delta may have a role, together with glycogen synthase kinase-3beta, in the pathogenesis of Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562708     DOI: 10.1074/jbc.M703269200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  154 in total

1.  Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Authors:  Jaya R P Prasanthi; Matthew Schrag; Bhanu Dasari; Gurdeep Marwarha; April Dickson; Wolff M Kirsch; Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Glycogen Synthase Kinase 3β-mediated Phosphorylation in the Most C-terminal Region of Protein Interacting with C Kinase 1 (PICK1) Regulates the Binding of PICK1 to Glutamate Receptor Subunit GluA2.

Authors:  Sosuke Yagishita; Miyuki Murayama; Tomoe Ebihara; Kei Maruyama; Akihiko Takashima
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

3.  FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease.

Authors:  Waltraud Mair; Jan Muntel; Katharina Tepper; Shaojun Tang; Jacek Biernat; William W Seeley; Kenneth S Kosik; Eckhard Mandelkow; Hanno Steen; Judith A Steen
Journal:  Anal Chem       Date:  2016-03-07       Impact factor: 6.986

4.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

5.  Pseudophosphorylation of tau protein directly modulates its aggregation kinetics.

Authors:  Edward Chang; Sohee Kim; Kelsey N Schafer; Jeff Kuret
Journal:  Biochim Biophys Acta       Date:  2010-10-23

6.  Programming with models: modularity and abstraction provide powerful capabilities for systems biology.

Authors:  Aneil Mallavarapu; Matthew Thomson; Benjamin Ullian; Jeremy Gunawardena
Journal:  J R Soc Interface       Date:  2009-03-06       Impact factor: 4.118

Review 7.  Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

Authors:  Pengfei Xu; Chiara Ianes; Fabian Gärtner; Congxing Liu; Timo Burster; Vasiliy Bakulev; Najma Rachidi; Uwe Knippschild; Joachim Bischof
Journal:  Gene       Date:  2019-07-31       Impact factor: 3.688

Review 8.  Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.

Authors:  Khalid Iqbal; M Omar Chohan; Inge Grundke-Iqbal
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 9.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Shotgun proteomics in neuroscience.

Authors:  Lujian Liao; Daniel B McClatchy; John R Yates
Journal:  Neuron       Date:  2009-07-16       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.